At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...

Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...

A new study shows that changes linked to Alzheimer’s disease can speed up with age in people’s late 50s, long before memory ...

A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.

The sub-study examined the impact of the therapy on prespecified Alzheimer’s plasma biomarkers in the subjects. Credit: ...

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

The Alzheimer's Arkansas Champions Award Luncheon on April 23 at Arkansas Federal Credit Union recognized the efforts of ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Oral NMDA receptor antagonist gets an expanded indication ...

Alzheimer's disease is best addressed as early as possible, ideally before symptoms become apparent. To enable early, ...

By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...

The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...